Transitioning historically inpatient chemotherapy regimens for hematologic malignancies to the ambulatory care setting

Am J Health Syst Pharm. 2018 Nov 15;75(22):1824-1830. doi: 10.2146/ajhp180060. Epub 2018 Aug 21.

Authors

Donald C Moore¹, Justin R Arnall², Dragos C Plesca²

Affiliations

¹ Department of Pharmacy, Levine Cancer Institute, Atrium Health, Charlotte, NC [email protected].
² Department of Pharmacy, Levine Cancer Institute, Atrium Health, Charlotte, NC.

PMID: 30131323
DOI: 10.2146/ajhp180060

No abstract available

Keywords: ambulatory care setting; chemotherapy; hematologic malignancies; medication safety.

MeSH terms

Ambulatory Care* / methods
Antineoplastic Agents / administration & dosage*
Antineoplastic Agents / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cisplatin / administration & dosage
Cisplatin / therapeutic use
Cyclophosphamide / administration & dosage
Cyclophosphamide / therapeutic use
Doxorubicin / administration & dosage
Doxorubicin / therapeutic use
Etoposide / administration & dosage
Etoposide / therapeutic use
Hematologic Neoplasms / drug therapy*
Hospitalization
Humans
Prednisone / administration & dosage
Prednisone / therapeutic use
Vincristine / administration & dosage
Vincristine / therapeutic use

Substances

Antineoplastic Agents
Vincristine
Etoposide
Doxorubicin
Cyclophosphamide
Cisplatin
Prednisone

Supplementary concepts

CAE-P protocol
EPOCH protocol